Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 19/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | FABP1 | P07148 | 6/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790391 | 0.92 | NR1H4 (0.51) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL17839774 | 0.82 | NR1H4 (0.47) | NR1H4RETFABP1FABP4 | |
| SCHEMBL1096115 | 0.80 | NR1H4 (0.58) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL20031245 | 0.80 | NR1H4 (0.45) | NR1H4RETFABP1FABP4 | |
| SCHEMBL19230638 | 0.77 | NR1H4 (0.41) | NR1H4RETFABP1FABP4HSD17B13 | |
| SCHEMBL19899995 | 0.77 | NR1H4 (0.50) | NR1H4RET | |
| SCHEMBL19899937 | 0.77 | NR1H4 (0.51) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL21216846 | 0.77 | NR1H4 (0.46) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL22790233 | 0.77 | NR1H4 (0.47) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL17839653 | 0.76 | RET (0.42) | NR1H4RETFABP1FABP4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-08-04 | — | — | US | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-109311849-B | Compounds that modulate FXR (NR1H4) | 吉利德科学公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3730487-A1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | Gilead Sciences, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3730487-A1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | Gilead Sciences, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20190315729-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315729-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| EP-3468962-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017218337-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017218337-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 446/4885FABP1 15/4885 |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 446/4885FABP1 15/4885 |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 446/4885FABP1 15/4885 |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 446/4885FABP1 15/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 845/4885FABP1 48/4885 |
| US-20190315729-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 446/4885FABP1 15/4885 |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885RET 446/4885FABP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.